RxDoctor Payments Data

Harsimran Gill, MD

Internal Medicine · Bakersfield, CANPI 1558603290

Payments from drug & device makers

$1,342in general payments, 2019–2025

Across 70 payments — averaging $19.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$219
  • Astellas Pharma US Inc$188
  • Pfizer$181
  • Johnson & Johnson$153
  • GSK$110
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$96
  • plus $394 from 9 others

What the payments were for

  • Food & beverage$1,20390%
  • Education$13910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,342 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$225,362
Medicare patients
475
Services billed
2,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide175$176,717
Enbrel SureclickEtanercept11$79,796
EliquisApixaban94$78,562
FarxigaDapagliflozin Propanediol76$70,659
JardianceEmpagliflozin60$67,156
RybelsusSemaglutide21$41,638
TrulicityDulaglutide34$40,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$36,270
XareltoRivaroxaban35$33,313
MounjaroTirzepatide22$23,593
Praluent PenAlirocumab29$22,291
TradjentaLinagliptin19$21,392
Spiriva RespimatTiotropium Bromide13$6,484
Levothyroxine Sodium467$6,073
Breo ElliptaFluticasone/Vilanterol13$5,990

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$70$95,03292 claims
PfizerEliquis$181$78,56294 claims
AstraZenecaFarxiga$219$70,65976 claims
Lilly USA, LLCTrulicity, Mounjaro$62$64,47956 claims
GSKTrelegy Ellipta, Breo Ellipta$110$42,25965 claims
Johnson & JohnsonXarelto$153$33,31335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →